Start with a free account for 3 free CME credits. Already a subscriber? Sign in.
Free Episode

COVID-19 - IDSA Treatment Guidelines, Remdesivir, and a Look Back

Neda Frayha, MD and Devang Patel, MD
00:00
23:52

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

 In this Hippo Education update, Primary Care RAP host Dr. Neda Frayha interviews regular guest and Infectious Diseases expert Dr. Devang Patel for a discussion of where the IDSA stands on all the potential treatments for COVID-19, a review of the remdesivir paper that is all the rage lately, and a look back on whether or not their very first conversations on the novel coronavirus have stood the test of time. 

Recommendation 1
Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends hydroxychloroquine/chloroquine in the context of a clinical trial. (Knowledge gap)
Recommendation 2
Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends hydroxychloroquine/chloroquine plus azithromycin only in the context of a clinical trial. (Knowledge gap)
Recommendation 3
Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends the combination of lopinavir/ritonavir only in the context of a clinical trial. (Knowledge gap)
Recommendation 4
Among patients who have been admitted to the hospital with COVID-19 pneumonia, the IDSA guideline panel suggests against the use of corticosteroids. (Conditional recommendation, very low certainty of evidence)
Recommendation 5
Among patients who have been admitted to the hospital with ARDS due to COVID-19, the IDSA guideline panel recommends the use of corticosteroids in the context of a clinical trial. (Knowledge gap)
Recommendation 6
Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends tocilizumab only in the context of a clinical trial. (Knowledge gap)
Recommendation 7
Among patients who have been admitted to the hospital with COVID-19, the IDSA guideline panel recommends COVID-19 convalescent plasma in the context of a clinical trial. (Knowledge gap)

Released 5/12/20

References:

Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Published April 11, 2020. Accessed May 2, 2020. 

 

National Institutes of Health. NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19?utm_source=The+Scope&utm_campaign=525dfe3ddf-Weekly_Scope_Jan_12_2018_COPY_01&utm_medium=email&utm_term=0_809ad7d22b-525dfe3ddf-180781593. Published April 29, 2020. Accessed May 2, 2020. 

 

Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multi-centre trial. The Lancet. Published April 29, 2020. DOI: https://doi.org/10.1016/S0140-6736(20)31022-9 

 

Patel D, Frayha N. COVID-19 Update. Hippo Education, March 2020. https://www.hippoed.com/pc/rap/episode/bonusshortcovid/covid19update


Patel D, Frayha N. Novel Coronavirus. Hippo Education, January 2020. https://www.hippoed.com/pc/rap/episode/bonusshortnovel/bonusshortnovel

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To download files, you need to subscribe.

Sign up today for full access to all episodes.